Sapere Bio Funding: How Much Did They Raise & Key Investors

How Much Did Sapere Bio Raise?
Funding & Key Investors

Sapere Bio has secured $114K in total funding, with its most recent capital infusion amounting to $114K. This major strategic investment underscores the company's significant progress and potential in its sector. The company's funding trajectory indicates a mature stage of development, likely focusing on scaling operations and market expansion.

What is Sapere Bio?

Sapere Bio

Business Services

Research & Development

Sapere Bio, originally known as HealthSpan Diagnostics, was established in 2013. Founded by Dr. Norman "Ned" Sharpless and Dr. Natalia Mitin, the company's genesis lies in pioneering research from Dr. Sharpless' laboratory at the Lineberger Cancer Center, University of North Carolina, Chapel Hill. The company is positioned within the biotechnology and diagnostics sector, likely focusing on developing innovative solutions derived from its foundational research.

How much funding has Sapere Bio raised?

Sapere Bio has raised a total of $114K across 1 funding round:

2021

Debt

$114K

Debt (2021): $114K with participation from PPP

Key Investors in Sapere Bio

PPP

Public-Private Partnership

What's next for Sapere Bio?

With a substantial total funding amount and a recent strategic investment, Sapere Bio is well-positioned for its next phase of growth. This capital infusion is expected to fuel further research and development, potentially leading to new product launches or market penetration strategies. The company's late-stage funding context suggests a focus on commercialization and scaling its operations to meet market demand and solidify its competitive advantage.

See full Sapere Bio company page

See More Financial Insights